Year |
Citation |
Score |
2019 |
Wang C, Buolamwini JK. A novel RNA variant of human concentrative nucleoside transporter 1 (hCNT1) that is a potential cancer biomarker. Experimental Hematology & Oncology. 8: 18. PMID 31440421 DOI: 10.1186/S40164-019-0144-Y |
0.352 |
|
2015 |
Nag S, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, Buolamwini JK, Wang W, Zhang R. Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. Biomedical Chromatography : Bmc. 29: 654-63. PMID 25294254 DOI: 10.1002/Bmc.3327 |
0.521 |
|
2014 |
Playa H, Lewis TA, Ting A, Suh BC, Muñoz B, Matuza R, Passer BJ, Schreiber SL, Buolamwini JK. Dilazep analogues for the study of equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2). Bioorganic & Medicinal Chemistry Letters. 24: 5801-4. PMID 25454272 DOI: 10.1016/J.Bmcl.2014.10.026 |
0.486 |
|
2014 |
Wang W, Qin JJ, Voruganti S, Srivenugopal KS, Nag S, Patil S, Sharma H, Wang MH, Wang H, Buolamwini JK, Zhang R. The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. Nature Communications. 5: 5086. PMID 25271708 DOI: 10.1038/Ncomms6086 |
0.6 |
|
2014 |
Wang W, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, Zhou J, Wang H, Mukhopadhyay D, Buolamwini JK, Zhang R. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice. Gastroenterology. 147: 893-902.e2. PMID 25016295 DOI: 10.1053/J.Gastro.2014.07.001 |
0.596 |
|
2014 |
Sun S, Playa HC, Deokar HS, Lin W, Buolamwini JK. Abstract 4478: Biopharmaceutic studies of novel nucleoside transporter inhibitor prodrugs that can protect against nucleoside drug-induced mitochondrial toxicity Cancer Research. 74: 4478-4478. DOI: 10.1158/1538-7445.Am2014-4478 |
0.547 |
|
2013 |
Chen Q, Buolamwini JK, Smith JC, Li A, Xu Q, Cheng X, Wei D. Impact of resistance mutations on inhibitor binding to HIV-1 integrase. Journal of Chemical Information and Modeling. 53: 3297-307. PMID 24205814 DOI: 10.1021/Ci400537N |
0.317 |
|
2013 |
Sharma H, Sanchez TW, Neamati N, Detorio M, Schinazi RF, Cheng X, Buolamwini JK. Synthesis, docking, and biological studies of phenanthrene β-diketo acids as novel HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry Letters. 23: 6146-51. PMID 24091080 DOI: 10.1016/J.Bmcl.2013.09.009 |
0.619 |
|
2013 |
Wang C, Lin W, Playa H, Sun S, Cameron K, Buolamwini JK. Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochemical Pharmacology. 86: 1531-40. PMID 24021350 DOI: 10.1016/J.Bcp.2013.08.063 |
0.653 |
|
2013 |
Lu C, Liu D, Jin J, Deokar H, Zhang Y, Buolamwini JK, Yu X, Yan C, Chen X. Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. Biochemical Pharmacology. 85: 1246-56. PMID 23415900 DOI: 10.1016/J.Bcp.2013.02.003 |
0.38 |
|
2012 |
Yang X, Wang W, Qin JJ, Wang MH, Sharma H, Buolamwini JK, Wang H, Zhang R. JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21. Plos One. 7: e34303. PMID 22558087 DOI: 10.1371/Journal.Pone.0034303 |
0.567 |
|
2012 |
Sharma H, Cheng X, Buolamwini JK. Homology model-guided 3D-QSAR studies of HIV-1 integrase inhibitors. Journal of Chemical Information and Modeling. 52: 515-44. PMID 22256860 DOI: 10.1021/Ci200485A |
0.613 |
|
2012 |
Wang W, Yang X, Zhang X, Wang M, Sharma H, Buolamwini JK, Zhang R. Abstract 3834: JKA97, a novel anti-cancer candidate, induces G1 arrest via up-regulation of p21 in a p53-independent manner Cancer Research. 72: 3834-3834. DOI: 10.1158/1538-7445.Am2012-3834 |
0.559 |
|
2011 |
Lin W, Buolamwini JK. Design, synthesis, and evaluation of 2-diethanolamino-4,8-diheptamethyleneimino-2-(N-aminoethyl-N-ethanolamino)-6-(N,N-diethanolamino)pyrimido[5,4-d]pyrimidine-fluorescein conjugate (8MDP-fluor), as a novel equilibrative nucleoside transporter probe. Bioconjugate Chemistry. 22: 1221-7. PMID 21539390 DOI: 10.1021/Bc2000758 |
0.556 |
|
2011 |
Sharma H, Patil S, Sanchez TW, Neamati N, Schinazi RF, Buolamwini JK. Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry. 19: 2030-45. PMID 21371895 DOI: 10.1016/J.Bmc.2011.01.047 |
0.612 |
|
2011 |
Wang H, Ma X, Ren S, Buolamwini JK, Yan C. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Molecular Cancer Therapeutics. 10: 69-79. PMID 21075910 DOI: 10.1158/1535-7163.Mct-10-0581 |
0.385 |
|
2010 |
Passer BJ, Cheema T, Zhou B, Wakimoto H, Zaupa C, Razmjoo M, Sarte J, Wu S, Wu CL, Noah JW, Li Q, Buolamwini JK, Yen Y, Rabkin SD, Martuza RL. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Research. 70: 3890-5. PMID 20424118 DOI: 10.1158/0008-5472.Can-10-0155 |
0.379 |
|
2010 |
Wang C, Pimple S, Buolamwini JK. Interaction of benzopyranone derivatives and related compounds with human concentrative nucleoside transporters 1, 2 and 3 heterologously expressed in porcine PK15 nucleoside transporter deficient cells. Structure-activity relationships and determinants of transporter affinity and selectivity. Biochemical Pharmacology. 79: 307-20. PMID 19735647 DOI: 10.1016/J.Bcp.2009.08.028 |
0.514 |
|
2009 |
Okamura T, Singh S, Buolamwini J, Haystead T, Friedman H, Bigner D, Ali-Osman F. Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. The Journal of Biological Chemistry. 284: 16979-89. PMID 19254954 DOI: 10.1074/Jbc.M808153200 |
0.319 |
|
2009 |
Gupte A, Buolamwini JK. Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 917-21. PMID 19097778 DOI: 10.1016/J.Bmcl.2008.11.112 |
0.71 |
|
2009 |
Gupte A, Buolamwini JK. CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1). Bioorganic & Medicinal Chemistry Letters. 19: 314-8. PMID 19091561 DOI: 10.1016/J.Bmcl.2008.11.092 |
0.694 |
|
2008 |
Hevener KE, Ball DM, Buolamwini JK, Lee RE. Quantitative structure-activity relationship studies on nitrofuranyl anti-tubercular agents. Bioorganic & Medicinal Chemistry. 16: 8042-53. PMID 18701298 DOI: 10.1016/J.Bmc.2008.07.070 |
0.392 |
|
2008 |
Zhu Z, Buolamwini JK. Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity. Bioorganic & Medicinal Chemistry. 16: 3848-65. PMID 18289860 DOI: 10.1016/J.Bmc.2008.01.044 |
0.636 |
|
2008 |
Luo W, Liu J, Li J, Zhang D, Liu M, Addo JK, Patil S, Zhang L, Yu J, Buolamwini JK, Chen J, Huang C. Anti-cancer effects of JKA97 are associated with its induction of cell apoptosis via a Bax-dependent and p53-independent pathway. The Journal of Biological Chemistry. 283: 8624-33. PMID 18218619 DOI: 10.1074/Jbc.M707860200 |
0.382 |
|
2007 |
Gupte A, Buolamwini JK. Novel C2-purine position analogs of nitrobenzylmercaptopurine riboside as human equilibrative nucleoside transporter 1 inhibitors. Bioorganic & Medicinal Chemistry. 15: 7726-37. PMID 17881236 DOI: 10.1016/J.Bmc.2007.08.058 |
0.706 |
|
2007 |
Lin W, Buolamwini JK. Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors. Journal of Medicinal Chemistry. 50: 3906-20. PMID 17636949 DOI: 10.1021/Jm070311L |
0.645 |
|
2007 |
Zhu Z, Hofmann PA, Buolamwini JK. Cardioprotective effects of novel tetrahydroisoquinoline analogs of nitrobenzylmercaptopurine riboside in an isolated perfused rat heart model of acute myocardial infarction. American Journal of Physiology. Heart and Circulatory Physiology. 292: H2921-6. PMID 17293492 DOI: 10.1152/ajpheart.01191.2005 |
0.535 |
|
2007 |
Patil S, Kamath S, Sanchez T, Neamati N, Schinazi RF, Buolamwini JK. Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry. 15: 1212-28. PMID 17158051 DOI: 10.1016/J.Bmc.2006.11.026 |
0.406 |
|
2006 |
Kamath S, Buolamwini JK. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Medicinal Research Reviews. 26: 569-94. PMID 16788977 DOI: 10.1002/Med.20070 |
0.31 |
|
2005 |
Gupte A, Buolamwini JK, Yadav V, Chu CK, Naguib FN, el Kouni MH. 6-Benzylthioinosine analogues: promising anti-toxoplasmic agents as inhibitors of the mammalian nucleoside transporter ENT1 (es). Biochemical Pharmacology. 71: 69-73. PMID 16310172 DOI: 10.1016/J.Bcp.2005.10.031 |
0.686 |
|
2005 |
Buolamwini JK, Addo J, Kamath S, Patil S, Mason D, Ores M. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Current Cancer Drug Targets. 5: 57-68. PMID 15720190 DOI: 10.2174/1568009053332672 |
0.427 |
|
2004 |
Addo JK, Buolamwini JK. Design, synthesis, and evaluation of 5'-S-aminoethyl-N(6)- azidobenzyl-5'-thioadenosine biotin conjugate: a bifunctional photoaffinity probe for the es nucleoside transporter. Bioconjugate Chemistry. 15: 536-40. PMID 15149181 DOI: 10.1021/Bc034165J |
0.425 |
|
2004 |
Gupte A, Buolamwini JK. Novel halogenated nitrobenzylthioinosine analogs as es nucleoside transporter inhibitors. Bioorganic & Medicinal Chemistry Letters. 14: 2257-60. PMID 15081020 DOI: 10.1016/J.Bmcl.2004.02.016 |
0.718 |
|
2004 |
Kuo CL, Assefa H, Kamath S, Brzozowski Z, Slawinski J, Saczewski F, Buolamwini JK, Neamati N. Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors. Journal of Medicinal Chemistry. 47: 385-99. PMID 14711310 DOI: 10.1021/Jm030378I |
0.419 |
|
2003 |
Assefa H, Kamath S, Buolamwini JK. 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Journal of Computer-Aided Molecular Design. 17: 475-93. PMID 14703120 DOI: 10.1023/B:Jcam.0000004622.13865.4F |
0.343 |
|
2003 |
Kamath S, Buolamwini JK. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors. Journal of Medicinal Chemistry. 46: 4657-68. PMID 14561085 DOI: 10.1021/Jm030065N |
0.397 |
|
2003 |
Zhu Z, Furr J, Buolamwini JK. Synthesis and flow cytometric evaluation of novel 1,2,3,4-tetrahydroisoquinoline conformationally constrained analogues of nitrobenzylmercaptopurine riboside (NBMPR) designed for probing its conformation when bound to the es nucleoside transporter. Journal of Medicinal Chemistry. 46: 831-7. PMID 12593662 DOI: 10.1021/Jm020405P |
0.647 |
|
2002 |
Buolamwini JK, Assefa H. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. Journal of Medicinal Chemistry. 45: 841-52. PMID 11831895 DOI: 10.1021/Jm010399H |
0.404 |
|
2001 |
Wang H, Prasad G, Buolamwini JK, Zhang R. Antisense anticancer oligonucleotide therapeutics. Current Cancer Drug Targets. 1: 177-196. PMID 12188878 DOI: 10.2174/1568009013334133 |
0.302 |
|
1999 |
Raghavan K, Kahn SD, Buolamwini JK. Building a hypothesis for nucleotide transport inhibitors Acs Symposium Series. 719: 153-164. |
0.391 |
|
1997 |
Buolamwini JK. Nucleoside transport inhibitors: Structure-activity relationships and potential therapeutic applications Current Medicinal Chemistry. 4: 35-66. |
0.407 |
|
Low-probability matches (unlikely to be authored by this person) |
2017 |
Kumar Deokar H, Barch HP, Buolamwini JK. Homology Modeling of Human Concentrative Nucleoside Transporters (hCNTs) and Validation by Virtual Screening and Experimental Testing to Identify Novel hCNT1 Inhibitors. Drug Designing : Open Access. 6. PMID 29167753 DOI: 10.4172/2169-0138.1000146 |
0.293 |
|
2018 |
Deokar H, Deokar M, Wang W, Zhang R, Buolamwini JK. QSAR Studies of New Pyrido[3,4-]indole Derivatives as Inhibitors of Colon and Pancreatic Cancer Cell Proliferation. Medicinal Chemistry Research : An International Journal For Rapid Communications On Design and Mechanisms of Action of Biologically Active Agents. 27: 2466-2481. PMID 31360052 DOI: 10.1007/s00044-018-2250-5 |
0.284 |
|
1990 |
Buolamwini JK, Knaus EE. Synthesis and antinociceptive activity of 4-pyridyl and -dihydropyridyl analogues of meperidine and ketobemidone Drug Design and Delivery. 7: 19-31. PMID 1982918 |
0.278 |
|
2005 |
Thimmaiah KN, Easton JB, Germain GS, Morton CL, Kamath S, Buolamwini JK, Houghton PJ. Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. The Journal of Biological Chemistry. 280: 31924-35. PMID 16009706 DOI: 10.1074/jbc.M507057200 |
0.276 |
|
2013 |
Wang C, Schwab LP, Fan M, Seagroves TN, Buolamwini JK. Chemoprevention activity of dipyridamole in the MMTV-PyMT transgenic mouse model of breast cancer. Cancer Prevention Research (Philadelphia, Pa.). 6: 437-47. PMID 23447563 DOI: 10.1158/1940-6207.Capr-12-0345 |
0.273 |
|
1997 |
Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, Van Osdol WW, Monks AP, Scudiero DA, Sausville EA, et al. An information-intensive approach to the molecular pharmacology of cancer Science. 275: 343-349. PMID 8994024 DOI: 10.1126/Science.275.5298.343 |
0.272 |
|
2005 |
Kamath SA, Buolamwini JK. Asp746 to glycine change may have a greater influence than Cys751 to serine change in accounting for ligand selectivity between EGFR and HER-2 at the ATP site. Journal of Computer-Aided Molecular Design. 19: 287-91. PMID 16184431 DOI: 10.1007/S10822-005-5083-5 |
0.271 |
|
1993 |
Jamieson GP, Brocklebank AM, Snook MB, Sawyer WH, Buolamwini JK, Paterson ARP, Wiley JS. Flow cytometric quantitation of nucleoside transporter sites on human leukemic cells Cytometry. 14: 32-38. PMID 8432200 DOI: 10.1002/cyto.990140107 |
0.27 |
|
2017 |
Patil SA, Addo JK, Deokar H, Sun S, Wang J, Li W, Suttle DP, Wang W, Zhang R, Buolamwini JK. Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b]indole Derivatives as Broad-Spectrum Potent Anticancer Agents. Drug Designing : Open Access. 6. PMID 29354330 DOI: 10.4172/2169-0138.1000143 |
0.27 |
|
2003 |
Buolamwini JK, Assefa H. Overview of novel anticancer drug targets. Methods in Molecular Medicine. 85: 3-28. PMID 12710193 DOI: 10.1385/1-59259-380-1:03 |
0.269 |
|
2000 |
Buolamwini JK. Cell cycle molecular targets in novel anticancer drug discovery Current Pharmaceutical Design. 6: 379-392. PMID 10788588 |
0.268 |
|
2023 |
Deokar H, Deokar M, Buolamwini JK. Integration of fingerprint-based similarity searching and kernel-based partial least squares analysis to predict inhibitory activity against CSK, HER2, JAK1, JAK2, and JAK3. Molecular Diversity. PMID 36648693 DOI: 10.1007/s11030-022-10596-1 |
0.259 |
|
2022 |
Wang Y, Yang C, Sims MM, Sacher JR, Raje M, Deokar H, Yue P, Turkson J, Buolamwini JK, Pfeffer LM. SS-4 is a highly selective small molecule inhibitor of STAT3 tyrosine phosphorylation that potently inhibits GBM tumorigenesis in vitro and in vivo. Cancer Letters. 533: 215614. PMID 35245627 DOI: 10.1016/j.canlet.2022.215614 |
0.251 |
|
2014 |
Nag S, Qin JJ, Patil S, Deokar H, Buolamwini JK, Wang W, Zhang R. A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 969: 235-40. PMID 25195025 DOI: 10.1016/J.Jchromb.2014.08.030 |
0.249 |
|
2006 |
Buolamwini JK. Microwave Assisted Organic Synthesis Edited by Jason P. Tierney and Pelle Lidstrom. Blackwell Publishing, Oxford, U.K. 2005. xi + 280 pp. 18 × 21 cm. ISBN 0-8493-2371-1. £89.50. Journal of Medicinal Chemistry. 49: 7922-7923. DOI: 10.1021/Jm068048W |
0.242 |
|
1995 |
Raghavan K, Buolamwini JK, Fesen MR, Pommier Y, Kohn KW, Weinstein JN. Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: A comparative molecular field analysis (CoMFA) study Journal of Medicinal Chemistry. 38: 890-897. PMID 7699704 |
0.238 |
|
2005 |
Buolamwini JK, Kamath S. Molecule-kinase interaction map. Nature Biotechnology. 23: 1346; author reply 1. PMID 16273056 DOI: 10.1038/Nbt1105-1346A |
0.23 |
|
2000 |
Weinstein JN, Buolamwini JK. Molecular targets in cancer drug discovery: Cell-based profiling Current Pharmaceutical Design. 6: 473-483. PMID 10788592 |
0.224 |
|
2020 |
Punganuru SR, Artula V, Zhao W, Rajaei M, Deokar H, Zhang R, Buolamwini JK, Srivenugopal KS, Wang W. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action. Cells. 9. PMID 32630235 DOI: 10.3390/cells9071592 |
0.214 |
|
1997 |
Myers TG, Anderson NL, Waltham M, Li G, Buolamwini JK, Scudiero DA, Paull KD, Sausville EA, Weinstein JN. A protein expression database for the molecular pharmacology of cancer Electrophoresis. 18: 647-653. PMID 9150955 DOI: 10.1002/elps.1150180351 |
0.214 |
|
1994 |
Buolamwini JK, Craik JD, Wiley JS, Robins MJ, Gati WP, Cass CE, Paterson ARP. Conjugates of fluorescein and SAENTA (5'-S-(2-aminoethyl)-N6-(4- nitrobenzyl)-5'-thioadenosine): Flow cytometry probes for the es nucleoside transporter elements of the plasma membrane Nucleosides and Nucleotides. 13: 737-751. DOI: 10.1080/15257779408013276 |
0.212 |
|
1999 |
Buolamwini JK. Novel anticancer drug discovery Current Opinion in Chemical Biology. 3: 500-509. PMID 10419854 DOI: 10.1016/S1367-5931(99)80073-8 |
0.205 |
|
2006 |
Buolamwini JK. A Survey of Novel Molecular Targets for Anticancer Drug Discovery Novel Anticancer Agents. 1-35. DOI: 10.1016/B978-012088561-9/50002-8 |
0.197 |
|
1988 |
Buolamwini JK, Knaus EE. Synthesis and antinociceptive activity of 7-aryloxysulfonyl piperidines Drug Design and Delivery. 3: 35-47. PMID 3255323 |
0.195 |
|
1996 |
Buolamwini JK, Raghavan K, Fesen MR, Pommier Y, Kohn KW, Weinstein JN. Application of the electrotopological state index to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors Pharmaceutical Research. 13: 1892-1895. PMID 8987091 DOI: 10.1023/A:1016005813432 |
0.192 |
|
2020 |
Wang W, Wang X, Rajaei M, Youn JY, Zafar A, Deokar H, Buolamwini JK, Yang J, Foster JH, Zhou J, Zhang R. Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action. Cancers. 12. PMID 33291373 DOI: 10.3390/cancers12123651 |
0.187 |
|
2012 |
Luo W, Liu J, Li J, Zhang D, Liu M, Addo JK, Patil S, Zhang L, Yu J, Buolamwini JK, Chen J, Huang C. Anti-cancer effects of JKA97 are associated with its induction of cell apoptosis via a Bax-dependent and p53-independent pathway (Journal of Biological Chemistry (2008) 283, (8624-8633)) Journal of Biological Chemistry. 287: 23850. DOI: 10.1074/jbc.A112.707860 |
0.181 |
|
2006 |
Patil S, Buolamwini JK. Recent uses of palladium chemistry in indole synthesis Current Organic Synthesis. 3: 477-498. DOI: 10.2174/157017906778699495 |
0.177 |
|
1997 |
Buolamwini JK, Barchi JJ. Solution NMR conformational analysis of the potent equilibrative sensitive (ES) nucleoside transporter inhibitor, S6-(4- nitrobenzyl)mercaptopurine riboside (NBMPR) Nucleosides and Nucleotides. 16: 2101-2110. DOI: 10.1080/07328319708002561 |
0.175 |
|
2001 |
Wang H, Prasad G, Buolamwini JK, Zhang R. Antisense anticancer oligonucleotide therapeutics Current Cancer Drug Targets. 1: 177-196. |
0.171 |
|
2018 |
Qin JJ, Wang W, Li X, Deokar H, Buolamwini JK, Zhang R. Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. Frontiers in Pharmacology. 9: 5. PMID 29387014 DOI: 10.3389/fphar.2018.00005 |
0.168 |
|
1992 |
Buolamwini JK, Knaus EE. Synthesis and antinociceptive activity of 1-[2-(pyridyl)ethyl] and 1-[2-(dihydropyridyl)ethyl] analogues of fentanyl Drug Design and Discovery. 8: 301-312. PMID 1445995 |
0.165 |
|
2008 |
Buolamwini JK. Book Review of Name Reactions for Functional Group Transformations Journal of Medicinal Chemistry. 51: 1074-1076. DOI: 10.1021/Jm701581T |
0.16 |
|
2000 |
Buolamwini JK. Molecular targets for novel anticancer drug discovery: Preface Current Pharmaceutical Design. 6. |
0.146 |
|
1991 |
Buolamwini JK, Knaus EE. Synthesis and antinociceptive activity of 2- and 3-methyl derivatives of 4-(pyridyl) isosteres of meperidine Drug Design and Discovery. 8: 145-156. PMID 1793776 |
0.124 |
|
1997 |
Zjawiony JK, Khalil AA, Clark AM, Hufford CD, Buolamwini JK. Studies on Methoxylation in the 7H-Naphtho[1,2,3-i,j] [2,7]naphthyridin-7-one System Journal of Heterocyclic Chemistry. 34: 1233-1237. |
0.076 |
|
2001 |
Bedir E, Calis I, Dunbar C, Sharan R, Buolamwini JK, Khan IA. Two novel cycloartane-type triterpene glycosides from the roots of Astragalus prusianus Tetrahedron. 57: 5961-5966. DOI: 10.1016/S0040-4020(01)00607-X |
0.058 |
|
1997 |
Kombian SB, Saleh TM, Fiagbe NI, Chen X, Akabutu JJ, Buolamwini JK, Pittman QJ. Ibogaine and a total alkaloidal extract of Voacanga africana modulate neuronal excitability and synaptic transmission in the rat parabrachial nucleus in vitro. Brain Research Bulletin. 44: 603-10. PMID 9365804 DOI: 10.1016/S0361-9230(97)00284-0 |
0.04 |
|
2006 |
Adjei AA, Buolamwini JK. Preface Novel Anticancer Agents. DOI: 10.1016/B978-012088561-9/50001-6 |
0.012 |
|
Hide low-probability matches. |